Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**RSHO-X** is a THC-free CBD isolate liquid product developed by HempMeds, a subsidiary of Medical Marijuana, Inc., formulated as pure cannabidiol (CBD) blended with organic medium-chain triglyceride (MCT) oil derived from coconut oil to enhance bioavailability. It contains no detectable THC (<0.1%), making it compliant with strict cannabis regulations and safe for World Anti-Doping Agency standards, suitable for athletes, military personnel, and those subject to drug testing. A 2017 Mexican study by Dr. Saul Garza Morales on 39 children with Lennox-Gastaut syndrome using progressive doses up to 5-7 mg CBD/kg over 4 months reported 84% reduction in motor seizures, 53% with >75% reduction, and 17% with complete seizure elimination, with zero adverse effects—outperforming Epidiolex in efficacy and safety. Available in concentrations like 2500mg or 5000mg CBD per bottle, it is approved for import by Mexico's COFEPRIS as the first cannabis-based product there, and used for epilepsy, anti-inflammatory effects, antioxidant support, pain relief, and general wellness.[1][2][11]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on RSHO-X.